Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
Kamran MA Aziz Aseer Diabetes Center, Aseer Central Hospital, Ministry of Health, Abha, Saudi Arabia Abstract: Diabetes management during Ramadan fasting is challenging to the physician in terms of minimizing the risk of hypoglycemia. As compared to oral hypoglycemic agents (OHAs) and sulfonylureas...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-04-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Online Access: | http://www.dovepress.com/fasting-during-ramadan-efficacy-safety-and-patient-acceptability-of-vi-peer-reviewed-article-DMSO |
| _version_ | 1797935644090040320 |
|---|---|
| author | Aziz KMA |
| author_facet | Aziz KMA |
| author_sort | Aziz KMA |
| collection | DOAJ |
| description | Kamran MA Aziz Aseer Diabetes Center, Aseer Central Hospital, Ministry of Health, Abha, Saudi Arabia Abstract: Diabetes management during Ramadan fasting is challenging to the physician in terms of minimizing the risk of hypoglycemia. As compared to oral hypoglycemic agents (OHAs) and sulfonylureas (SUs), which carry a higher and significant risk of hypoglycemia, newer antidiabetic agents such as dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated lower risk of hypoglycemia during Ramadan fasting, with better patient compliance. In addition to diabetes education and pre-Ramadan assessments, the physician should also consider use of DPP-4 inhibitors (such as vildagliptin) during Ramadan fasting to minimize the risk of hypoglycemia in type 2 diabetic subjects. Severe episodes of hypoglycemia have been demonstrated in recent research and clinical trials with OHAs/SUs. Conversely, these research observations have also demonstrated comparative safety and efficacy with lower risk of hypoglycemia associated with vildagliptin. Current research review has collected evidence-based clinical trials and observations for the drug vildagliptin to minimize the risk of hypoglycemia during Ramadan fasting, while at the same time focusing the role of diabetes self-management education (DSME), pre-Ramadan assessments, and patient care. Keywords: hypoglycemia, DPP4-inhibitors, oral hypoglycemic agents, Ramadan fasting, type 2 diabetes, vildagliptin |
| first_indexed | 2024-04-10T18:17:19Z |
| format | Article |
| id | doaj.art-ce42027a5dff45f9a689e17a89fda098 |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T18:17:19Z |
| publishDate | 2015-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-ce42027a5dff45f9a689e17a89fda0982023-02-02T08:31:19ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072015-04-012015default20721121368Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patientsAziz KMAKamran MA Aziz Aseer Diabetes Center, Aseer Central Hospital, Ministry of Health, Abha, Saudi Arabia Abstract: Diabetes management during Ramadan fasting is challenging to the physician in terms of minimizing the risk of hypoglycemia. As compared to oral hypoglycemic agents (OHAs) and sulfonylureas (SUs), which carry a higher and significant risk of hypoglycemia, newer antidiabetic agents such as dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated lower risk of hypoglycemia during Ramadan fasting, with better patient compliance. In addition to diabetes education and pre-Ramadan assessments, the physician should also consider use of DPP-4 inhibitors (such as vildagliptin) during Ramadan fasting to minimize the risk of hypoglycemia in type 2 diabetic subjects. Severe episodes of hypoglycemia have been demonstrated in recent research and clinical trials with OHAs/SUs. Conversely, these research observations have also demonstrated comparative safety and efficacy with lower risk of hypoglycemia associated with vildagliptin. Current research review has collected evidence-based clinical trials and observations for the drug vildagliptin to minimize the risk of hypoglycemia during Ramadan fasting, while at the same time focusing the role of diabetes self-management education (DSME), pre-Ramadan assessments, and patient care. Keywords: hypoglycemia, DPP4-inhibitors, oral hypoglycemic agents, Ramadan fasting, type 2 diabetes, vildagliptinhttp://www.dovepress.com/fasting-during-ramadan-efficacy-safety-and-patient-acceptability-of-vi-peer-reviewed-article-DMSO |
| spellingShingle | Aziz KMA Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients Diabetes, Metabolic Syndrome and Obesity |
| title | Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients |
| title_full | Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients |
| title_fullStr | Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients |
| title_full_unstemmed | Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients |
| title_short | Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients |
| title_sort | fasting during ramadan efficacy safety and patient acceptability of vildagliptin in diabetic patients |
| url | http://www.dovepress.com/fasting-during-ramadan-efficacy-safety-and-patient-acceptability-of-vi-peer-reviewed-article-DMSO |
| work_keys_str_mv | AT azizkma fastingduringramadanefficacysafetyandpatientacceptabilityofvildagliptinindiabeticpatients |